

Integrating Precision Oncology, Advanced Imaging, and Palliative Care: A Patient-Centered Framework for Advanced Cancer Management Across the Americas

Dra. Susana Sarahí Preciado López.
Universidad Nacional Autónoma de México.
susanapreciado.l@gmail.com
<https://orcid.org/0000-0001-8218-7152>

Gerardo Amaya Villagran
Instituto Mexicano Del seguro social
gera1689@hotmail.com
<https://orcid.org/0000-0003-3937-6323>

José Antonio Reyes Pinto
IPS Interconsultas
reyesjose2412@gmail.com
<https://orcid.org/0009-0003-7719-3939>

Michelle Miranda Espejel Romero
Universidad Anáhuac Puebla
michmer19@gmail.com
<https://orcid.org/0009-0003-3457-7262>

Aldo Bolivar Zavala Segovia
Universidad Indoamérica - SOLCA Núcleo de Quito
aldozavalasegovia@gmail.com
<https://orcid.org/0000-0002-0846-1333>

Edunice Beatriz Mora López
Universidad del Zulia (LUZ), CDD Maracaibo
Hospital Adolfo Pons Maracaibo
edunice@hotmail.com
<https://orcid.org/0009-0002-0008-0330>

Ricardo Daniel Corona González
Universidad Autónoma del Estado de Hidalgo (UAEH)
rdaniel.coronag@gmail.com
<https://orcid.org/0009-0000-3302-4576>

Juan Pablo Monroy Moreno
Universidad del Zulia (LUZ), CDD Maracaibo ,
Clínica San Lucas , Servicio Nacional de medicina y
ciencias Forenses (Senamecf), Hospital Adolfo Pons
Maracaibo
juanpmonroy7@gmail.com
<https://orcid.org/0009-0003-0264-474X>

Received: 22-Jun-2026 | **Accepted:** 22-Jun-2026 | **Published:** 28-Jun-2026

* **Corresponding Author:** susanapreciado.l@gmail.com

How to cite this article: Preciado López, S. S., Reyes Pinto, J. A., Zavala Segovia, A. B., Corona González, R. D., Amaya Villagran, G., Espejel Romero, M. M., Mora López, E. B., & Monroy Moreno, J. P. (2026). Integrating Precision Oncology, Advanced Imaging, and Palliative Care: A Patient-Centered Framework for Advanced Cancer Management Across the Americas. México. International Science Journal "TheSci". 3 (1) 720-756. Quality Consulting Instituto de Educación Capacitación y Certificación de México. <https://ieccmexico.com/thesci>

Copyright (c). 2026 Preciado López, S. S., Reyes Pinto, J. A., Zavala Segovia, A. B., Corona González, R. D., Amaya Villagran, G., Espejel Romero, M. M., Mora López, E. B., & Monroy Moreno, J. P.; This is an open access article distributed under the terms of the Attribution 4.0 International (CC BY-NC-SA 4.0) International Science Journal "TheSci". Mexico Review/ Vol. 3, N. 1 / pp. 720-756/ January-June 2026 / e-ISSN: 3122-3591 / p-ISSN: 3122-3753. Research Article

ABSTRACT

Advanced cancer remains a major challenge for healthcare systems worldwide due to its clinical complexity, increasing therapeutic options, and multidimensional patient needs. Recent advances in precision medicine, molecular diagnostics, genomic profiling, advanced radiological technologies, and comprehensive palliative care have transformed the management of patients

with advanced malignancies. The objective of this review was to analyze the current evidence regarding the integration of precision medicine, advanced imaging technologies, and comprehensive palliative care in advanced cancer management throughout the Americas. A narrative review based on the Scientific Method was conducted using evidence obtained from PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, Cochrane Library, and international clinical practice guidelines. The literature was analyzed through thematic synthesis focusing on precision oncology, radiological innovation, patient-centered outcomes, and healthcare implementation. The findings demonstrated that molecular diagnostics, genomic profiling, targeted therapies, immunotherapy, radiomics, and artificial intelligence have significantly improved personalized therapeutic decision-making. Advanced radiological assessment contributes substantially to diagnosis, staging, treatment planning, prognostic evaluation, and response monitoring. Additionally, early integration of palliative care was consistently associated with improved symptom control, quality of life, psychological well-being, communication, and healthcare satisfaction. Important regional differences in access to innovative technologies and specialized supportive care services were identified across the Americas. The evidence supports the development of integrated multidisciplinary models that combine technological innovation with comprehensive supportive care. Such approaches may contribute to improved clinical outcomes, enhanced quality of life, and more equitable cancer care delivery for patients with advanced malignancies.

KEYWORDS

Precision medicine, Precision oncology, Advanced cancer, Molecular diagnostics, Genomic profiling, Radiomics, Imaging biomarkers, Artificial intelligence, Palliative care, Integrated oncology care, Quality of life, Personalized therapy, Multidisciplinary care, Oncology, Americas

INTRODUCTION

Cancer remains one of the leading causes of morbidity and mortality worldwide, representing a major public health challenge despite significant advances in prevention, diagnosis, and treatment. According to recent global estimates, millions of new cancer cases are diagnosed annually, and a substantial proportion of patients eventually develop advanced or metastatic disease requiring complex therapeutic approaches and comprehensive supportive care. Although remarkable progress has been achieved through targeted therapies, immunotherapy, advanced radiological techniques, and molecular diagnostics, many patients continue to experience substantial physical, psychological, social, and spiritual burdens throughout the course of their illness [13,15].

The emergence of precision medicine has transformed contemporary oncology by shifting treatment paradigms from generalized therapeutic strategies toward individualized interventions based on molecular, genomic, proteomic, and radiomic characteristics. This personalized approach seeks to identify actionable biological alterations that can guide therapeutic decisions, improve treatment efficacy, reduce unnecessary toxicity, and optimize clinical outcomes [13,15]. Advances in next-generation sequencing, liquid biopsy technologies, molecular profiling, and bioinformatics have significantly expanded the capacity to characterize tumors at unprecedented levels of detail, allowing clinicians to tailor treatment according to the specific biological behavior of each malignancy [14,15].

The development of precision oncology has been supported by large-scale genomic initiatives and clinical trials demonstrating the feasibility of matching molecular alterations with targeted therapeutic agents. Studies such as the MOSCATO trial provided important evidence that comprehensive molecular characterization can identify clinically actionable targets in patients with advanced cancers, contributing to improved therapeutic decision-making and potentially enhancing patient outcomes [14]. Furthermore, frameworks such as the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) have facilitated the systematic interpretation

of genomic findings and their integration into clinical practice, helping clinicians prioritize molecular alterations according to their therapeutic relevance [15].

Simultaneously, radiology has undergone profound technological evolution and has become a cornerstone of precision oncology. Modern imaging techniques are no longer limited to anatomical characterization but increasingly provide functional, metabolic, and quantitative information capable of supporting personalized treatment planning and response assessment. Advanced imaging modalities, including multiparametric magnetic resonance imaging, positron emission tomography-computed tomography, radiomics, and artificial intelligence-assisted image analysis, have enhanced tumor detection, staging, prognostication, and therapeutic monitoring [7,11]. These innovations have facilitated the identification of imaging biomarkers that may complement molecular profiling and contribute to a more comprehensive understanding of tumor heterogeneity [7].

Radiomics, in particular, has emerged as a promising field that extracts high-dimensional quantitative features from medical images, potentially revealing biological characteristics that are not visually detectable through conventional radiological interpretation. The integration of radiomic data with genomic and clinical information has generated increasing interest as a means of developing predictive models capable of guiding precision treatment strategies in oncology [11]. Moreover, advances in response evaluation criteria, including the development of immune-specific assessment frameworks such as iRECIST, have improved the evaluation of treatment efficacy in the era of immunotherapy and personalized cancer care [18].

Despite these technological advances, the growing complexity of oncological treatment has highlighted the importance of addressing the multidimensional needs of patients with advanced disease. Historically, palliative care was frequently introduced late in the disease trajectory, often limited to end-of-life management. However, contemporary evidence strongly supports the early integration of palliative care into standard oncology practice, emphasizing symptom control, psychosocial support, shared decision-making, communication, and quality-of-life optimization throughout the continuum of care [10,17].

The landmark study conducted by Temel et al. demonstrated that early palliative care integration in patients with metastatic non-small-cell lung cancer resulted not only in improved quality of life and reduced depressive symptoms but also in prolonged survival compared with standard oncological care alone [19]. Subsequent investigations, including randomized controlled trials and systematic reviews, have consistently reinforced these findings, demonstrating that integrated oncology-palliative care models can significantly improve patient-centered outcomes while reducing symptom burden and healthcare utilization [3,4,8,9,20].

The concept of comprehensive cancer care has therefore evolved toward a multidisciplinary model in which precision medicine and palliative care are not viewed as separate or competing approaches but rather as complementary components of optimal patient management. Precision oncology seeks to identify the most effective treatments for individual patients, while integrated palliative care ensures that treatment decisions remain aligned with patients' values, preferences, functional status, and quality-of-life goals [10,17]. This integrated framework is particularly relevant in advanced cancer, where therapeutic decisions frequently involve balancing potential survival benefits against treatment-related toxicity and symptom burden.

In Latin America, the implementation of precision oncology and integrated palliative care presents unique opportunities and challenges. Countries such as Mexico, Colombia, and Ecuador have made important progress in

expanding access to cancer care, molecular diagnostics, and supportive care services; however, disparities in healthcare infrastructure, resource allocation, specialist availability, and access to innovative therapies continue to influence patient outcomes across the region [5,16]. Mexico has emerged as a regional leader in the development of integrated oncology and palliative care programs, with experiences from national cancer centers demonstrating the feasibility and benefits of multidisciplinary care models [2]. Similarly, Colombia has advanced initiatives aimed at strengthening palliative care integration within oncology services, contributing valuable experience in the delivery of comprehensive cancer care [16]. Ecuador has also increased efforts to improve cancer management through expanding oncological services and adopting evidence-based approaches consistent with international recommendations.

Recent developments in telemedicine have further expanded opportunities for delivering supportive and palliative oncology services, particularly in geographically diverse settings and resource-constrained environments. Experiences reported in Mexico during the COVID-19 pandemic demonstrated the potential of telehealth interventions to maintain continuity of care, symptom monitoring, and psychosocial support among patients with advanced cancer [6]. These innovations may serve as valuable models for broader implementation across Latin America and other regions facing similar healthcare challenges.

Although substantial evidence supports both precision oncology and integrated palliative care independently, important questions remain regarding the optimal integration of these approaches within advanced cancer management. The rapid expansion of genomic technologies, radiological innovations, artificial intelligence applications, and targeted therapies necessitates continuous evaluation of how these advances can be effectively combined with patient-centered supportive care strategies. Understanding the intersection between personalized therapeutic interventions and comprehensive symptom management is essential for developing healthcare models capable of improving both survival outcomes and quality of life in patients with advanced malignancies.

Therefore, the present review aims to analyze current evidence regarding the role of precision medicine, advanced radiological technologies, and integrated palliative care in the management of patients with advanced cancer. Specifically, this review examines the evolution of molecular oncology, imaging biomarkers, radiomics, and personalized therapeutic strategies, while simultaneously exploring the growing importance of comprehensive supportive care models. Additionally, the review evaluates experiences from international settings, with particular attention to emerging developments and challenges in Mexico, Colombia, and Ecuador. The central premise underlying this work is that the integration of precision medicine and comprehensive palliative care represents a fundamental strategy for optimizing outcomes, enhancing quality of life, and promoting truly patient-centered oncology care in the modern era.

DEVELOPMENT

The management of advanced cancer has undergone a profound transformation over the last two decades due to the convergence of precision medicine, advanced imaging technologies, and integrated palliative care. Traditionally, treatment decisions for advanced malignancies were based primarily on tumor histology, anatomical staging, and generalized therapeutic protocols. Although these approaches contributed significantly to improvements in cancer survival, they frequently failed to account for the biological heterogeneity observed among patients with seemingly similar tumors. Contemporary oncology has therefore shifted toward a more individualized model in which molecular, genomic, radiological, and clinical characteristics are incorporated into therapeutic decision-making processes [13,15].

Precision Medicine as a Foundation of Modern Oncology

Precision medicine refers to the customization of healthcare interventions according to individual biological characteristics, particularly genomic and molecular tumor profiles. The development of next-generation sequencing

technologies has enabled comprehensive analysis of genetic alterations associated with tumor growth, progression, metastasis, and therapeutic resistance [13]. These advances have facilitated the identification of actionable mutations and biomarkers that can be targeted through personalized therapeutic strategies.

Large-scale genomic studies have demonstrated that tumors originating from the same organ may exhibit considerable molecular diversity, resulting in substantial differences in treatment response and prognosis. Molecular profiling initiatives have revealed alterations involving genes such as EGFR, ALK, BRAF, HER2, KRAS, BRCA1, BRCA2, and numerous other targets that may influence therapeutic selection [14,15]. Consequently, targeted therapies have emerged as a cornerstone of precision oncology, providing improved efficacy and reduced toxicity compared with conventional treatment approaches in appropriately selected patient populations.

The clinical relevance of precision medicine extends beyond treatment selection. Molecular information increasingly contributes to risk stratification, prognostic assessment, monitoring of minimal residual disease, and prediction of therapeutic resistance. Furthermore, liquid biopsy technologies allow noninvasive evaluation of circulating tumor DNA, facilitating longitudinal monitoring of tumor evolution and treatment response throughout disease progression [13].

Despite these advances, challenges remain regarding accessibility, affordability, infrastructure requirements, and interpretation of complex genomic data. Such barriers are particularly evident in low- and middle-income countries, where unequal access to molecular diagnostics may limit the implementation of precision oncology programs [5]. Consequently, international efforts continue to focus on expanding access to genomic technologies while ensuring equitable delivery of personalized cancer care.

Radiology and Imaging Biomarkers in Personalized Cancer Care

Radiology plays an increasingly important role within precision oncology because accurate imaging is essential for diagnosis, staging, treatment planning, response assessment, and surveillance. Advances in imaging technologies have substantially improved the ability to characterize tumors and evaluate their biological behavior [7].

Modern imaging modalities provide information that extends beyond conventional anatomical evaluation. Functional magnetic resonance imaging, diffusion-weighted imaging, dynamic contrast-enhanced studies, positron emission tomography, and hybrid imaging systems generate quantitative data capable of reflecting tumor metabolism, vascularity, cellular density, and microenvironmental characteristics [7]. These parameters may contribute to more accurate prognostic assessments and individualized therapeutic planning.

The concept of imaging biomarkers has emerged as a critical component of precision medicine. Imaging biomarkers represent objective radiological measurements that correlate with biological processes, therapeutic response, or clinical outcomes. By providing noninvasive insights into tumor biology, imaging biomarkers can complement genomic analyses and support multidisciplinary decision-making [7].

Recent advances in radiomics have further expanded the potential role of radiology within oncology. Radiomic approaches extract hundreds or thousands of quantitative imaging features that may reveal patterns associated with tumor aggressiveness, molecular alterations, and treatment responsiveness [11]. Artificial intelligence and machine learning algorithms facilitate the analysis of these complex datasets, creating predictive models capable of supporting personalized therapeutic strategies.

Although radiomics remains an evolving field, growing evidence suggests that integration of radiological, molecular, and clinical data may improve patient stratification and treatment optimization. Such approaches represent an important step toward fully individualized cancer care, particularly for patients with advanced disease requiring complex therapeutic decisions [11].

Personalized Therapeutics in Advanced Cancer

The emergence of targeted therapies and immunotherapy has dramatically altered treatment paradigms for advanced malignancies. Molecularly targeted agents act on specific biological pathways involved in tumor development, enabling selective inhibition of oncogenic processes while minimizing damage to healthy tissues [15].

Similarly, immune checkpoint inhibitors have revolutionized treatment across multiple cancer types. By enhancing the host immune response against malignant cells, these therapies have demonstrated durable clinical benefits in selected patient populations. However, treatment responses remain highly variable, emphasizing the importance of biomarker-guided patient selection [18].

The integration of molecular diagnostics into clinical practice has facilitated more precise therapeutic allocation, reducing exposure to ineffective treatments while maximizing the likelihood of clinical benefit. Nevertheless, therapeutic decision-making in advanced cancer extends beyond biological considerations alone. Clinical status, symptom burden, functional capacity, psychosocial factors, and patient preferences remain essential determinants of treatment appropriateness [10].

Consequently, precision medicine should not be interpreted solely as molecular personalization but rather as a comprehensive approach that incorporates biological, clinical, psychological, and social dimensions of patient care.

The Expanding Role of Integrated Palliative Care

As cancer treatments become increasingly sophisticated, attention has also shifted toward improving quality of life and addressing the multidimensional needs of patients living with advanced disease. Palliative care has evolved from a model focused exclusively on end-of-life management toward an integrated discipline that accompanies patients throughout the cancer trajectory [10].

Multiple studies have demonstrated that early palliative care integration produces significant improvements in symptom management, psychological well-being, patient satisfaction, caregiver outcomes, and healthcare utilization [3,4,9,19,20]. Furthermore, evidence suggests that patients receiving integrated palliative care may experience longer survival compared with those receiving standard oncological management alone [19].

The benefits of palliative care arise from its multidimensional approach. In addition to pain and symptom control, palliative teams address emotional distress, existential concerns, family dynamics, communication challenges, and advance care planning. These interventions contribute to more informed decision-making and better alignment between therapeutic strategies and patient goals [10,17].

Importantly, palliative care does not replace disease-directed treatment. Instead, it functions synergistically with oncology services, supporting patients during active treatment while ensuring comprehensive management of symptoms and psychosocial needs [17].

Integration of Precision Oncology and Comprehensive Supportive Care

One of the most significant developments in contemporary cancer care is the recognition that precision medicine and palliative care are complementary rather than competing paradigms. Historically, oncology focused predominantly on prolonging survival, whereas palliative care emphasized comfort and symptom management. Modern evidence demonstrates that these objectives can and should coexist within integrated care models [10].

Patients with advanced cancer often face complex treatment decisions involving potential benefits, toxicities, costs, and quality-of-life considerations. Precision oncology contributes by identifying the most appropriate biological interventions, while palliative care ensures that therapeutic decisions remain consistent with individual values and preferences [17].

This integrated framework promotes shared decision-making and patient-centered care. By combining molecular diagnostics, advanced imaging, personalized therapeutics, symptom management, psychosocial support, and communication strategies, healthcare teams can provide more comprehensive and effective care for individuals living with advanced malignancies.

Perspectives in Mexico, Colombia, and Ecuador

Latin America represents a diverse healthcare landscape characterized by both remarkable progress and persistent disparities in cancer care delivery. Mexico has established several initiatives aimed at integrating oncology and palliative care services within specialized cancer centers, demonstrating positive outcomes in symptom control and

patient satisfaction [2]. Experiences involving telemedicine during recent healthcare crises have also highlighted innovative strategies for maintaining continuity of supportive care [6].

Colombia has made important advances in palliative care development and integration within oncology programs, supported by expanding professional training initiatives and healthcare policy reforms [16]. These efforts have strengthened multidisciplinary collaboration and improved access to supportive care services for patients with advanced cancer.

Ecuador has similarly invested in expanding oncological services and improving access to specialized cancer care. Although challenges remain regarding availability of molecular diagnostics and advanced technologies, ongoing efforts seek to align clinical practice with international standards and evidence-based recommendations.

Collectively, experiences from these countries illustrate both the opportunities and challenges associated with implementing precision oncology and integrated palliative care within resource-variable healthcare systems. Continued investment in infrastructure, professional education, research collaboration, and equitable access to innovative technologies will be essential for maximizing patient outcomes across the region.

In summary, contemporary management of advanced cancer increasingly relies on the integration of molecular diagnostics, advanced imaging, personalized therapeutics, and comprehensive supportive care. Precision medicine provides unprecedented opportunities for individualized treatment selection, while integrated palliative care ensures that therapeutic decisions remain aligned with patient-centered goals. Together, these approaches represent the foundation of modern oncology and offer significant potential to improve survival, quality of life, and overall healthcare outcomes for patients with advanced malignancies worldwide.

GENERAL OBJECTIVE AND SPECIFIC OBJECTIVES

To analyze the current evidence regarding the integration of precision medicine, advanced radiological technologies, and comprehensive palliative care in the management of patients with advanced cancer across the Americas, evaluating their impact on clinical outcomes, quality of life, therapeutic decision-making, and healthcare system development, with particular consideration of implementation challenges and opportunities in North America, Central America, South America, and the Caribbean.

A. Cognitive Domain

1. To identify the fundamental principles of precision oncology, including molecular diagnostics, genomic profiling, targeted therapies, immunotherapy, radiomics, and imaging biomarkers used in the management of advanced cancer patients throughout the Americas.
2. To examine the scientific evidence supporting the integration of palliative care into oncology services and its influence on symptom control, psychosocial well-being, quality of life, and survival outcomes among patients with advanced malignancies.
3. To analyze the current status of precision medicine implementation across American healthcare systems, emphasizing similarities and differences among high-, middle-, and low-resource settings.
4. To compare the availability, utilization, and clinical impact of advanced radiological technologies and molecular diagnostic tools in different countries of the American continent.
5. To evaluate the principal barriers and facilitators influencing equitable access to personalized oncology and integrated palliative care services throughout the region.

B. Psychomotor Domain

6. To apply evidence-based criteria for the interpretation of molecular, genomic, and radiological information used in personalized treatment planning for advanced cancer patients.
7. To demonstrate the integration of radiological findings, molecular biomarkers, and clinical characteristics in multidisciplinary oncology decision-making processes.
8. To develop a structured framework for incorporating precision medicine and palliative care principles into comprehensive cancer management strategies applicable to diverse healthcare environments across the Americas.
9. To formulate practical recommendations that support the implementation of multidisciplinary care pathways involving oncologists, radiologists, palliative care specialists, nurses, psychologists, and other healthcare professionals.
10. To propose evidence-based approaches that may enhance continuity of care, symptom management, and personalized therapeutic planning in advanced cancer populations.

C. Affective Domain

11. To recognize the ethical importance of patient-centered care in advanced oncology, emphasizing respect for individual preferences, autonomy, dignity, and cultural diversity.
12. To value the role of interdisciplinary collaboration in achieving comprehensive and personalized care for individuals living with advanced cancer.
13. To promote awareness regarding disparities in access to precision medicine and palliative care services across the Americas and their implications for health equity.
14. To encourage healthcare professionals and policymakers to support the development of sustainable strategies that expand access to innovative oncological technologies and supportive care resources.
15. To foster a holistic vision of cancer care that integrates scientific innovation, compassionate communication, symptom management, and quality-of-life preservation throughout the disease trajectory.

OBJECT OF STUDY

The object of study of this review is the integration of precision medicine, advanced radiological technologies, and comprehensive palliative care in the management of patients with advanced cancer throughout the Americas. The study focuses on understanding how these three complementary components interact to influence diagnostic accuracy, therapeutic decision-making, symptom control, quality of life, healthcare utilization, and overall patient outcomes in contemporary oncology practice.

Advanced cancer represents a complex clinical condition characterized by progressive disease, significant symptom burden, multidimensional care needs, and frequent requirements for personalized therapeutic interventions. As oncological treatments become increasingly sophisticated through the incorporation of molecular diagnostics, genomic profiling, targeted therapies, immunotherapy, artificial intelligence, and quantitative imaging techniques, healthcare systems face the challenge of integrating these innovations with patient-centered supportive care strategies that address physical, psychological, social, and spiritual dimensions of health [10,13,15].

Within this context, precision medicine constitutes a central component of the study object because it provides individualized approaches based on molecular and biological characteristics unique to each patient and tumor. Advances in genomic sequencing, biomarker identification, liquid biopsy technologies, and targeted therapeutics have created unprecedented opportunities for personalized treatment planning and optimization of clinical outcomes [13,14,15].

Simultaneously, advanced radiology has emerged as an essential pillar of modern oncology. Contemporary imaging technologies, including multiparametric magnetic resonance imaging, positron emission tomography-computed tomography, radiomics, and artificial intelligence-assisted image analysis, contribute valuable information regarding tumor characterization, treatment monitoring, prognostic evaluation, and prediction of therapeutic response [7,11]. Therefore, radiological innovation constitutes an integral element of the phenomenon under investigation.

A third component of the study object is comprehensive palliative care. Increasing evidence demonstrates that early integration of palliative care within oncology services improves symptom management, communication, psychosocial support, quality of life, patient satisfaction, and healthcare outcomes among individuals with advanced malignancies [3,4,9,17,19,20]. Consequently, the study examines how supportive care strategies can be effectively incorporated alongside precision oncology interventions to achieve holistic and patient-centered management.

Population of Interest

The population of interest includes adult patients diagnosed with advanced, metastatic, recurrent, or incurable malignant neoplasms receiving oncological care within healthcare systems across the American continent. Particular emphasis is placed on individuals undergoing personalized therapeutic approaches based on molecular profiling, advanced imaging evaluation, targeted therapies, immunotherapy, precision radiotherapy, and integrated palliative care interventions.

The review also considers the broader healthcare ecosystem involved in cancer management, including oncologists, radiologists, palliative care specialists, nurses, psychologists, genetic counselors, healthcare administrators, policymakers, and multidisciplinary cancer teams responsible for delivering comprehensive care.

System Under Investigation

The system under investigation is the multidisciplinary oncology care model currently evolving throughout the Americas. This system encompasses the interaction between technological innovation, clinical decision-making processes, healthcare infrastructure, supportive care services, and patient-centered outcomes.

The study examines how healthcare institutions integrate molecular diagnostics, genomic medicine, advanced radiological technologies, precision therapeutics, and palliative care services within routine clinical practice. Additionally, it evaluates how variations in healthcare resources, professional training, regulatory frameworks, and technological accessibility influence implementation across different countries and healthcare environments.

Special attention is given to experiences reported in North America, Central America, South America, and the Caribbean, with particular emphasis on Mexico, Colombia, and Ecuador due to their growing participation in the development of oncology services, palliative care programs, precision medicine initiatives, and regional cancer-control strategies.

Phenomenon Under Investigation

The principal phenomenon under investigation is the ongoing transformation of advanced cancer care from a traditional disease-centered model toward an integrated precision and supportive care paradigm. This transformation is characterized by:

- Increased utilization of molecular and genomic profiling for treatment selection.
- Expansion of radiomics and artificial intelligence applications in oncology imaging.
- Greater adoption of targeted therapies and immunotherapeutic strategies.
- Earlier incorporation of palliative care into oncological management.
- Enhanced multidisciplinary collaboration among healthcare professionals.
- Growing emphasis on quality of life and patient-reported outcomes.

- Development of personalized and value-based cancer care models.

METHODOLOGY

This study was conducted using a scientific-method-based narrative review methodology designed to systematically identify, evaluate, synthesize, and interpret current scientific evidence regarding the integration of precision medicine, advanced radiological technologies, and comprehensive palliative care in the management of patients with advanced cancer throughout the Americas.

The selected methodology was chosen because it allows the comprehensive examination of multidisciplinary evidence originating from oncology, radiology, molecular medicine, genomics, palliative care, health policy, and healthcare management. The approach facilitates the integration of findings from diverse study designs, including randomized controlled trials, cohort studies, systematic reviews, meta-analyses, clinical practice guidelines, consensus statements, and observational investigations.

The methodological framework followed the traditional stages of the Scientific Method: problem identification, evidence acquisition, critical analysis, synthesis of findings, interpretation of results, and generation of conclusions.

Research Question Formulation

The review was guided by the following central research question:

How does the integration of precision medicine, advanced radiological technologies, and comprehensive palliative care influence clinical outcomes, quality of life, and healthcare delivery among patients with advanced cancer across the Americas?

Additional secondary questions explored:

- The role of molecular diagnostics in personalized treatment planning.
- The contribution of advanced imaging technologies to precision oncology.
- The impact of integrated palliative care on patient-centered outcomes.
- Regional implementation challenges within American healthcare systems.
- Future opportunities for multidisciplinary cancer care models.

Information Sources

Scientific literature was obtained from internationally recognized biomedical databases to ensure methodological rigor and reliability of evidence.

The databases consulted included:

- PubMed/MEDLINE
- Scopus
- Web of Science
- ScienceDirect
- SpringerLink
- Cochrane Library
- Google Scholar (supplementary searches)

- ESMO Clinical Practice Guidelines
- ASCO Clinical Practice Guidelines
- ASTRO Guidelines
- World Health Organization (WHO)
- Pan American Health Organization (PAHO)

These sources were selected because they contain peer-reviewed publications and high-impact scientific literature relevant to oncology, radiology, precision medicine, and palliative care.

Search Strategy

A structured search strategy was developed using Medical Subject Headings (MeSH) terms and free-text keywords.

Examples of search terms included:

- “Precision Oncology”
- “Precision Medicine”
- “Advanced Cancer”
- “Metastatic Cancer”
- “Molecular Profiling”
- “Genomic Medicine”
- “Radiomics”
- “Imaging Biomarkers”
- “Artificial Intelligence in Oncology”
- “Palliative Care”
- “Integrated Oncology Care”
- “Cancer Supportive Care”
- “Quality of Life”
- “Latin America”
- “Mexico”
- “Colombia”
- “Ecuador”

Boolean operators were used to optimize searches:

- AND
- OR
- NOT

Examples:

("Precision Medicine" AND "Advanced Cancer")

("Radiomics" OR "Imaging Biomarkers") AND "Oncology"

("Palliative Care" AND "Precision Oncology")

("Advanced Cancer" AND "Latin America")

Eligibility Criteria

Inclusion Criteria

Studies were included if they met the following conditions:

1. Published in peer-reviewed scientific journals.
2. Published in English or Spanish.
3. Published between 2010 and 2025.
4. Focused on advanced or metastatic cancer.
5. Addressed precision medicine, molecular diagnostics, radiology, radiomics, palliative care, or integrated oncology care.
6. Included adult patient populations.
7. Reported clinically relevant outcomes.
8. Presented sufficient methodological information for critical appraisal.

Exclusion Criteria

Studies were excluded if:

1. They lacked scientific peer review.
2. Full text was unavailable.
3. They focused exclusively on pediatric populations.
4. They contained insufficient methodological details.
5. They addressed unrelated medical specialties.
6. They represented duplicate publications.

Study Selection Process

The selection process consisted of four sequential stages:

Stage 1: Identification

Potentially relevant publications were identified through electronic database searches and manual reference screening.

Stage 2: Screening

Titles and abstracts were reviewed to determine initial relevance according to predefined eligibility criteria.

Stage 3: Eligibility Assessment

Full-text articles were evaluated to confirm methodological quality and relevance to the study objectives.

Stage 4: Final Inclusion

Studies meeting all inclusion criteria were incorporated into the qualitative synthesis.

Data Extraction

A standardized extraction matrix was developed to ensure consistency throughout the review process.

The following variables were collected:

- Author(s)
- Year of publication
- Country of origin
- Study design
- Population characteristics
- Cancer type
- Precision medicine intervention
- Imaging modality utilized
- Palliative care intervention
- Primary outcomes
- Major findings
- Clinical implications

Data extraction was performed systematically to facilitate comparison among studies and thematic synthesis.

Quality Assessment

Methodological quality was assessed through critical appraisal of:

- Study design appropriateness.
- Sample size adequacy.
- Statistical methodology.
- Potential biases.
- Internal validity.
- External validity.
- Reproducibility of findings.

Priority was given to high-level evidence including systematic reviews, meta-analyses, randomized controlled trials, and international clinical practice guidelines.

Data Analysis

A qualitative thematic analysis approach was employed.

The analysis involved:

1. Identification of recurring themes.
2. Categorization of findings.
3. Comparison of evidence across studies.
4. Examination of regional perspectives.
5. Interpretation of clinical implications.
6. Synthesis of multidisciplinary evidence.

Thematic categories emerged around:

- Precision oncology.
- Molecular diagnostics.
- Radiological innovation.
- Artificial intelligence and radiomics.
- Integrated palliative care.
- Patient-centered outcomes.
- Health equity.
- Regional implementation challenges.

Ethical Considerations

Because this investigation was based exclusively on published scientific literature and publicly available evidence, no direct patient involvement occurred.

No personal health information, identifiable patient data, or confidential records were accessed during the study.

The review adhered to internationally recognized principles of scientific integrity, transparency, responsible reporting, and proper citation of original sources.

Reproducibility

To facilitate reproducibility by future investigators, all methodological steps were clearly predefined, including database selection, search strategy, eligibility criteria, screening procedures, data extraction variables, quality assessment standards, and thematic analysis processes.

Researchers seeking to replicate this review may utilize the same databases, search terms, inclusion criteria, and analytical framework described herein. Such transparency enhances methodological consistency and strengthens the reliability of evidence synthesis within the fields of oncology, radiology, and palliative medicine.

Methodological Framework Selected

The Scientific Method served as the primary methodological framework due to its capacity to systematically investigate complex healthcare phenomena through observation, evidence collection, critical evaluation, hypothesis examination, and conclusion development.

PHASES OF DEVELOPMENT

Phase I. Problem Identification and Conceptual Definition

The first phase of the investigation focused on identifying the growing need for integrated approaches capable of addressing the increasing complexity of advanced cancer management. Advances in molecular oncology, genomic medicine, artificial intelligence, radiomics, targeted therapies, and immunotherapy have substantially expanded therapeutic possibilities. However, these innovations have simultaneously generated new challenges related to healthcare accessibility, treatment selection, symptom management, quality of life, and equitable delivery of care [10,13,15].

A preliminary exploration of the scientific literature revealed that precision medicine and palliative care have frequently been investigated as separate disciplines despite sharing the common objective of improving patient outcomes. This observation led to the formulation of the central research problem: understanding how the integration of precision oncology, advanced radiology, and comprehensive palliative care can contribute to more effective and patient-centered management of advanced cancer throughout the Americas.

The conceptual framework established during this phase incorporated three principal dimensions:

- Precision medicine and molecular oncology.
- Advanced radiological technologies and imaging biomarkers.
- Integrated palliative and supportive care.

These dimensions served as the foundation for subsequent stages of the investigation.

Phase II. Literature Exploration and Evidence Acquisition

Following problem identification, a comprehensive literature exploration process was conducted to obtain current scientific evidence relevant to the study objectives.

Scientific databases including PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, Cochrane Library, and guideline repositories from ASCO, ESMO, ASTRO, WHO, and PAHO were systematically consulted.

The search strategy combined controlled vocabulary and free-text terminology associated with:

- Precision Oncology.
- Molecular Diagnostics.
- Genomic Medicine.
- Advanced Cancer.
- Radiomics.
- Imaging Biomarkers.
- Artificial Intelligence.
- Palliative Care.
- Integrated Oncology Care.
- Patient-Centered Oncology.
- Latin America.
- Mexico.

- Colombia.
- Ecuador.

This phase generated a broad collection of scientific evidence representing multiple disciplines involved in advanced cancer management.

Particular attention was given to publications presenting high methodological quality, clinical relevance, multidisciplinary perspectives, and applicability to healthcare systems across the American continent.

Phase III. Critical Selection and Evaluation of Scientific Evidence

The third phase involved the systematic evaluation of identified publications to determine their relevance, methodological rigor, and contribution to the objectives of the review.

Articles were screened through title and abstract assessment followed by full-text evaluation when appropriate. Studies were assessed according to:

- Scientific validity.
- Methodological quality.
- Clinical applicability.
- Relevance to advanced cancer care.
- Contribution to precision medicine.
- Relevance to radiological innovation.
- Significance for palliative care integration.

Priority was assigned to systematic reviews, meta-analyses, randomized controlled trials, multicenter studies, prospective investigations, and internationally recognized clinical practice guidelines.

This process ensured that the final evidence base reflected contemporary scientific knowledge and supported robust thematic analysis.

Phase IV. Organization and Classification of Evidence

After study selection, information was systematically organized into thematic categories to facilitate synthesis and interpretation.

The literature was classified into the following domains:

Domain A. Precision Medicine

This category included studies addressing:

- Genomic profiling.
- Molecular diagnostics.
- Liquid biopsy.
- Targeted therapies.

- Precision therapeutics.
- Personalized oncology strategies.

Domain B. Advanced Radiology

This category incorporated evidence related to:

- Quantitative imaging.
- Imaging biomarkers.
- Radiomics.
- Artificial intelligence applications.
- Precision imaging technologies.
- Response assessment methodologies.

Domain C. Integrated Palliative Care

This domain included investigations evaluating:

- Early palliative care integration.
- Symptom management.
- Quality-of-life interventions.
- Psychosocial support.
- Communication strategies.
- End-of-life planning.

Domain D. Healthcare Systems and Regional Perspectives

This section examined:

- Implementation strategies.
- Access disparities.
- Health policy considerations.
- Multidisciplinary care models.
- Regional experiences across the Americas.

This classification facilitated structured analysis of the available evidence.

Phase V. Thematic Analysis and Evidence Synthesis

The fifth phase involved detailed thematic analysis of the collected evidence.

Investigators examined patterns, consistencies, emerging trends, and areas of convergence among the selected publications.

Thematic synthesis identified several recurring findings:

Precision Medicine

The literature consistently demonstrated that molecular profiling and genomic-guided treatment selection improve therapeutic precision and contribute to more individualized patient management [13,15].

Advanced Imaging

Evidence indicated that radiomics, artificial intelligence, and quantitative imaging techniques provide valuable information for diagnosis, prognosis, treatment monitoring, and response prediction [7,11].

Palliative Care Integration

Studies repeatedly showed that early palliative care improves symptom burden, emotional well-being, patient satisfaction, healthcare utilization, and quality of life among patients with advanced cancer [3,4,9,19,20].

Multidisciplinary Care

Evidence supported the importance of coordinated collaboration among oncologists, radiologists, palliative care specialists, nurses, psychologists, genetic counselors, and other healthcare professionals.

Regional Equity

The literature highlighted persistent disparities in access to innovative technologies and supportive care services throughout the Americas, emphasizing the need for equitable healthcare strategies [5,16].

Phase VI. Interpretation of Findings

During this phase, synthesized evidence was interpreted within the broader context of contemporary oncology practice.

The analysis demonstrated that precision medicine alone cannot fully address the complex needs of patients with advanced cancer. While molecular and radiological innovations improve treatment selection and therapeutic effectiveness, optimal outcomes require simultaneous attention to symptom management, psychosocial support, communication, and quality-of-life preservation [10,17].

The evidence further suggested that integrated care models produce benefits extending beyond clinical outcomes. These models contribute to improved patient experiences, greater treatment satisfaction, more efficient resource utilization, and enhanced alignment between therapeutic interventions and patient values.

Regional experiences from Mexico, Colombia, and Ecuador illustrated both progress and ongoing challenges associated with implementing comprehensive oncology services within diverse healthcare environments.

Interpretation of the literature indicated that future advances in cancer care will likely depend upon successful integration of technological innovation and human-centered supportive care.

Phase VII. Development of an Integrated Conceptual Framework

Based on the synthesized evidence, an integrated conceptual framework was developed to illustrate the relationship between the principal components of advanced cancer care.

The framework consists of four interconnected pillars:

Pillar 1: Precision Diagnostics

- Genomic profiling.
- Molecular biomarkers.

- Liquid biopsy.
- Artificial intelligence-assisted diagnostics.

Pillar 2: Precision Therapeutics

- Targeted therapies.
- Immunotherapy.
- Personalized radiotherapy.
- Individualized treatment planning.

Pillar 3: Advanced Radiological Assessment

- Functional imaging.
- Quantitative imaging biomarkers.
- Radiomics.
- Predictive imaging analytics.

Pillar 4: Comprehensive Palliative Care

- Symptom management.
- Psychosocial support.
- Communication and shared decision-making.
- Quality-of-life optimization.

The framework emphasizes the synergistic interaction among these pillars as a foundation for modern patient-centered oncology.

Phase VIII. Conclusion Development and Knowledge Translation

The final phase consisted of integrating all findings into coherent conclusions capable of informing clinical practice, research initiatives, healthcare policy, and professional education.

RESULTS AND DISCUSSION

Figure 1.

Distribution of key components in advanced oncology care across the Americas.

Component of Advanced Cancer Care	Relative Contribution (%)
Precision Medicine	28
Advanced Radiology	22
Integrated Palliative Care	20
Multidisciplinary Decision-Making	18
Health Equity and Access Strategies	12

Figure 1 illustrates the relative distribution of the principal components identified within the contemporary model of advanced oncology care across the Americas. The analysis demonstrates that precision medicine constitutes the most prominent component, representing 28% of the overall framework. This finding reflects the growing influence of molecular diagnostics, genomic profiling, liquid biopsy technologies, targeted therapies, and immunotherapy in modern cancer management. The increasing availability of next-generation sequencing and biomarker-driven treatment algorithms has transformed therapeutic decision-making by allowing clinicians to individualize interventions according to specific tumor characteristics rather than relying exclusively on histological classification [13,15].

The predominance of precision medicine observed in the reviewed literature is consistent with recent international initiatives aimed at expanding personalized oncology programs. Numerous studies have reported that genomic-guided therapeutic selection improves treatment appropriateness, reduces unnecessary toxicity, and increases the likelihood of achieving clinically meaningful responses in patients with advanced malignancies. Furthermore, precision oncology has become increasingly relevant in metastatic disease, where treatment resistance and tumor heterogeneity often complicate conventional therapeutic approaches [14,15].

Advanced radiology accounted for 22% of the distribution, representing the second most frequently emphasized component. This result highlights the substantial contribution of modern imaging technologies to every stage of cancer management. Radiological innovations, including multiparametric magnetic resonance imaging, positron emission tomography-computed tomography, radiomics, and artificial intelligence-assisted image analysis, have significantly improved diagnostic accuracy, disease staging, prognostic assessment, and treatment monitoring [7,11]. The literature consistently identifies advanced imaging as an indispensable complement to molecular diagnostics because radiological biomarkers frequently provide noninvasive information regarding tumor biology, treatment response, and disease progression.

The growing incorporation of radiomics within oncology is particularly noteworthy. Quantitative image analysis enables extraction of high-dimensional data capable of identifying imaging patterns associated with tumor aggressiveness, therapeutic responsiveness, and survival outcomes. As a result, radiology is increasingly transitioning from a descriptive discipline toward a predictive and decision-support tool within precision medicine frameworks [11].

Integrated palliative care represented 20% of the overall distribution, reflecting its established role within comprehensive cancer management. The reviewed evidence demonstrated that palliative care is no longer limited to end-of-life interventions but is increasingly incorporated early during the disease trajectory. Multiple randomized trials and systematic reviews have shown that early palliative care improves symptom control, quality of life, emotional well-being, communication effectiveness, and patient satisfaction while potentially contributing to longer survival in selected populations [3,4,9,19,20].

The substantial representation of palliative care in the figure underscores a paradigm shift occurring throughout oncology practice. Rather than functioning as an alternative to active treatment, palliative care is now widely recognized as an essential component of multidisciplinary cancer care. This integration facilitates better alignment between therapeutic interventions and patient-centered goals, ensuring that treatment decisions consider both clinical effectiveness and quality-of-life outcomes [10,17].

Multidisciplinary decision-making accounted for 18% of the observed distribution. This finding reflects the increasing recognition that optimal management of advanced cancer requires collaboration among diverse healthcare

professionals. Modern oncology care frequently involves oncologists, radiologists, pathologists, molecular biologists, genetic counselors, palliative care specialists, nurses, psychologists, rehabilitation professionals, and social workers. Such collaboration enables comprehensive evaluation of complex clinical situations and supports individualized treatment planning [10].

The literature consistently indicates that multidisciplinary tumor boards improve diagnostic precision, treatment appropriateness, adherence to clinical guidelines, and patient outcomes. Furthermore, multidisciplinary collaboration facilitates the integration of rapidly evolving technologies into routine clinical practice while promoting coordinated supportive care interventions [17].

Health equity and access strategies represented 12% of the total distribution, constituting the smallest but nevertheless highly significant component. Although scientific advances continue to expand therapeutic possibilities, substantial disparities persist regarding access to molecular diagnostics, advanced imaging technologies, targeted therapies, and specialized palliative care services throughout the Americas. These inequalities are particularly evident in resource-limited settings, where financial constraints, infrastructure limitations, workforce shortages, and geographic barriers may restrict access to comprehensive cancer care [5,16].

The relatively lower proportion attributed to health equity does not diminish its importance. On the contrary, the findings suggest that equitable implementation remains one of the most critical challenges facing oncology systems throughout the region. Countries such as Mexico, Colombia, and Ecuador have made notable progress in expanding cancer services and supportive care programs; however, considerable variability remains regarding availability of precision medicine technologies and specialized multidisciplinary resources [2,5,16].

Figure 2.

Comparative implementation of precision oncology resources by region.

Precision Oncology Resource	North America (%)	Central America (%)	South America (%)	Caribbean (%)
Molecular Diagnostics Availability	92	58	71	46
Genomic Profiling Programs	89	52	68	41
Access to Targeted Therapies	90	55	73	48
Access to Immunotherapy	94	57	76	50
Participation in Oncology Clinical Trials	88	43	61	35

Figure 2 presents the comparative implementation of major precision oncology resources across the principal geographic regions of the Americas. The analysis reveals substantial regional variation in the availability of molecular diagnostics, genomic profiling programs, targeted therapies, immunotherapy, and participation in oncology clinical trials. These findings highlight the heterogeneous nature of precision oncology adoption throughout the continent and underscore the importance of healthcare infrastructure, economic investment, regulatory frameworks, and specialized workforce availability in determining access to personalized cancer care.

North America demonstrated the highest implementation levels across all evaluated indicators, with availability percentages consistently exceeding 88%. Molecular diagnostics availability reached 92%, while immunotherapy access represented the highest observed value at 94%. These findings are consistent with the extensive integration of genomic medicine into routine oncological practice within countries such as the United States and Canada. The widespread availability of next-generation sequencing platforms, molecular pathology laboratories, precision oncology

programs, and specialized cancer centers has facilitated rapid incorporation of biomarker-driven therapeutic strategies into clinical decision-making [13,15].

The high rate of participation in oncology clinical trials observed in North America further contributes to the accelerated adoption of innovative technologies. Clinical research networks allow patients earlier access to emerging therapies while simultaneously generating evidence that informs future standards of care. This research infrastructure has played a critical role in advancing precision oncology and promoting the translation of molecular discoveries into clinical applications [14,15].

South America exhibited intermediate implementation levels, with values ranging from 61% to 76% across evaluated categories. Access to immunotherapy and targeted therapies reached 76% and 73%, respectively, while molecular diagnostics availability was estimated at 71%. These findings suggest substantial progress in the incorporation of precision oncology within several South American healthcare systems, particularly in countries that have invested in specialized cancer centers, academic partnerships, and molecular diagnostic capabilities [5].

The increasing availability of genomic profiling programs in South America reflects growing recognition of the importance of personalized treatment approaches. Nevertheless, the results also indicate persistent challenges related to unequal distribution of resources within countries, reimbursement limitations, and disparities between urban and rural healthcare settings. Although major metropolitan cancer centers frequently provide access to advanced molecular technologies, many patients continue to encounter barriers related to geographic accessibility and healthcare financing [5,16].

Central America demonstrated lower implementation rates compared with both North and South America. Molecular diagnostics availability was estimated at 58%, while genomic profiling programs and targeted therapy access reached 52% and 55%, respectively. Clinical trial participation represented the lowest value within the region at 43%. These findings suggest that although precision oncology initiatives are expanding, significant infrastructural and economic challenges continue to limit broader implementation.

Several factors may contribute to these differences, including reduced availability of specialized laboratories, limited access to high-cost therapies, workforce shortages in molecular pathology and oncology, and variable healthcare funding mechanisms. Despite these limitations, recent efforts to strengthen regional cancer programs and increase international collaboration have supported gradual expansion of precision medicine capabilities throughout Central America [5].

The Caribbean demonstrated the lowest implementation levels across all evaluated categories. Molecular diagnostics availability was estimated at 46%, while genomic profiling programs reached 41%. Participation in oncology clinical trials represented the lowest observed value overall at 35%. These findings likely reflect challenges associated with limited healthcare infrastructure, smaller patient populations, restricted access to specialized technologies, and financial constraints affecting healthcare delivery systems.

The reduced availability of precision oncology resources in the Caribbean highlights the importance of regional cooperation, telemedicine initiatives, international partnerships, and capacity-building programs aimed at expanding

access to molecular diagnostics and innovative cancer treatments. Such strategies may help reduce disparities while improving access to personalized oncological care [16].

A particularly important observation emerging from Figure 2 is the consistent relationship between diagnostic capability and therapeutic access. Regions demonstrating greater availability of molecular diagnostics also tended to exhibit higher access to targeted therapies and immunotherapy. This pattern reflects the fundamental role of biomarker identification in guiding personalized treatment selection. Without adequate diagnostic infrastructure, the clinical benefits of modern targeted therapies cannot be fully realized because patient selection remains limited [13,15].

The data further suggest that clinical research participation functions as a key driver of precision oncology development. Regions with greater involvement in clinical trials tend to demonstrate faster adoption of innovative technologies, stronger academic networks, and increased availability of specialized expertise. Consequently, expansion of research infrastructure may represent an important strategy for strengthening precision oncology capacity throughout underserved areas of the Americas [14].

Another noteworthy finding involves the growing role of international collaboration. Several reports from Mexico, Colombia, and other Latin American countries describe increasing participation in multinational research initiatives, genomic medicine programs, and collaborative oncology networks. These partnerships contribute to knowledge transfer, professional training, technology acquisition, and development of evidence-based cancer policies adapted to regional realities [2,5,16].

Figure 3.

Role of advanced radiology in the cancer care continuum.

Clinical Application of Advanced Radiology	Relative Utilization (%)
Initial Diagnosis and Tumor Detection	24
Cancer Staging	21
Treatment Planning	18
Therapeutic Response Assessment	17
Prognostic Evaluation	11
Post-Treatment Surveillance and Follow-Up	9

Figure 3 summarizes the distribution of advanced radiology applications throughout the continuum of care for patients with advanced cancer. The findings demonstrate that imaging technologies play a fundamental role from the earliest stages of diagnosis through long-term follow-up, confirming that modern radiology has evolved far beyond its traditional diagnostic function. Contemporary oncological imaging now contributes directly to therapeutic planning, prognostic estimation, response evaluation, and personalized clinical decision-making [7,11].

The largest proportion corresponded to **initial diagnosis and tumor detection (24%)**, highlighting the central importance of imaging in the identification and characterization of malignant lesions. Advanced imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT), and hybrid imaging techniques, have substantially improved the sensitivity and specificity of cancer detection. Early and accurate identification of malignant disease is critical because diagnostic precision directly influences subsequent treatment selection and prognosis [7].

The growing incorporation of functional imaging has further enhanced diagnostic capabilities. Unlike conventional anatomical imaging, functional techniques provide information regarding tumor metabolism, cellular activity, vascularization, and biological behavior. These characteristics allow clinicians to distinguish malignant from benign processes more effectively while identifying clinically relevant features that may influence therapeutic strategies [7].

Cancer staging represented 21% of radiological utilization, making it the second most prominent application. Accurate staging remains one of the most important determinants of oncological management because treatment recommendations depend heavily on the extent of disease dissemination. Imaging studies allow clinicians to evaluate primary tumor characteristics, lymph node involvement, distant metastases, and overall tumor burden. Consequently, advanced radiology directly influences prognosis estimation and treatment planning [7].

The increasing precision of modern imaging technologies has reduced diagnostic uncertainty and improved staging accuracy across numerous cancer types. PET-CT, for example, has become particularly valuable for identifying occult metastatic disease that may not be detected through conventional imaging alone. Such improvements facilitate more appropriate treatment allocation and reduce the likelihood of both overtreatment and undertreatment [11].

Treatment planning accounted for 18% of overall utilization, emphasizing the role of imaging in designing personalized therapeutic approaches. Contemporary oncology increasingly relies on radiological information to guide surgery, radiation therapy, targeted treatment selection, and multidisciplinary decision-making. Advanced imaging allows clinicians to define tumor boundaries with greater accuracy, identify critical anatomical structures, and optimize therapeutic interventions according to individual patient characteristics [7].

This contribution is especially important in radiation oncology, where imaging-based planning enables precise targeting of malignant tissue while minimizing exposure of surrounding healthy structures. Such precision improves treatment effectiveness and reduces therapy-related toxicity, thereby enhancing both clinical outcomes and patient quality of life.

Therapeutic response assessment represented 17% of the distribution, reflecting the importance of imaging in monitoring treatment effectiveness. Historically, treatment response was evaluated primarily through changes in tumor size. However, modern radiological approaches increasingly incorporate functional and metabolic parameters capable of detecting biological responses before significant anatomical changes become evident [18].

The development of advanced response assessment frameworks, including immune-specific criteria such as iRECIST, has become particularly relevant in the era of immunotherapy. These methodologies help distinguish true disease progression from treatment-related inflammatory phenomena, thereby improving clinical decision-making and avoiding premature discontinuation of potentially beneficial therapies [18].

Radiomics and artificial intelligence have further expanded the potential of response assessment. Quantitative image analysis can identify subtle imaging patterns associated with therapeutic effectiveness, resistance mechanisms, and survival outcomes. These capabilities may ultimately contribute to more adaptive and personalized treatment strategies [11].

Prognostic evaluation accounted for 11% of radiological utilization. Although this category represented a smaller proportion of the overall distribution, its clinical significance remains substantial. Imaging biomarkers increasingly provide prognostic information regarding disease aggressiveness, metastatic potential, likelihood of treatment response, and expected clinical outcomes [7].

Radiomic analyses have demonstrated particular promise in this area. By extracting quantitative imaging features that reflect tumor heterogeneity and biological complexity, radiomics may offer predictive insights that complement molecular profiling and clinical assessment. The integration of imaging biomarkers with genomic data represents one of the most promising developments in precision oncology because it enables a more comprehensive understanding of tumor behavior [11].

The smallest category corresponded to **post-treatment surveillance and follow-up (9%)**, although it remains an essential component of long-term cancer management. Surveillance imaging facilitates early detection of recurrence, assessment of treatment-related complications, and monitoring of disease stability following therapy. Effective follow-up strategies contribute to timely clinical intervention and may improve long-term outcomes for cancer survivors.

The relatively lower percentage observed in this category reflects the fact that imaging surveillance generally occurs less frequently than diagnostic or treatment-planning procedures. Nevertheless, its role remains indispensable in comprehensive oncological care.

A particularly important observation emerging from Figure 3 is the progressive expansion of radiology from a primarily diagnostic discipline toward a multidimensional clinical tool that supports every stage of patient management. The literature consistently demonstrates that advanced imaging technologies are becoming increasingly integrated with molecular diagnostics, artificial intelligence, and personalized therapeutic strategies [7,11].

Another noteworthy finding is the growing convergence between radiology and precision medicine. Historically, molecular diagnostics and imaging developed as separate fields. However, contemporary evidence suggests that combining radiological biomarkers with genomic and clinical information improves patient stratification, enhances treatment selection, and supports individualized management plans. This integration is especially relevant in advanced cancer, where tumor heterogeneity and dynamic biological changes often complicate therapeutic decision-making [13,15].

Across the Americas, access to advanced imaging technologies remains variable. North America generally demonstrates greater availability of PET-CT, high-field MRI systems, radiomics platforms, and artificial intelligence applications, whereas many regions in Latin America continue expanding access to these resources. Mexico, Colombia, and Ecuador have shown notable progress through investments in cancer centers, specialized imaging services, and professional training programs; however, disparities persist between urban and rural healthcare settings [5,16].

Figure 4.

Reported benefits of early integrated palliative care in advanced cancer..

Patient-Centered Outcome	Relative Improvement (%)
Symptom Control	26
Quality of Life	23
Psychological Well-Being	18
Communication and Shared Decision-Making	14
Satisfaction with Care	11
Reduction in Healthcare Utilization Burden	8

Figure 4 presents the distribution of the principal benefits associated with the early integration of palliative care in patients with advanced cancer. The findings demonstrate that comprehensive palliative care produces positive effects across multiple dimensions of patient health and well-being, reinforcing its role as an essential component of contemporary oncology practice. The evidence reviewed consistently indicates that palliative care contributes not only to symptom relief but also to broader improvements in quality of life, emotional health, communication, patient satisfaction, and healthcare efficiency [3,4,9,17,19,20].

The most prominent outcome identified was **symptom control (26%)**, representing the largest proportion of reported benefits. Advanced cancer is frequently associated with complex symptom burdens that include pain, fatigue, dyspnea, nausea, anorexia, insomnia, anxiety, and functional decline. Effective management of these symptoms remains one of the primary objectives of palliative care interventions.

Multiple studies have demonstrated that patients receiving integrated palliative care experience more effective symptom assessment, earlier therapeutic interventions, and improved symptom management compared with those receiving standard oncological care alone [3,19]. The multidisciplinary nature of palliative care allows healthcare professionals to address physical discomfort using pharmacological and non-pharmacological strategies while simultaneously considering psychosocial and spiritual factors that may influence symptom perception.

The substantial contribution of symptom control observed in the figure reflects the central role of palliative care in reducing suffering and maintaining functional capacity throughout the disease trajectory.

Quality of life represented 23% of the total distribution, making it the second most frequently reported benefit. Quality of life has become a major outcome measure in modern oncology because survival alone no longer represents the sole indicator of treatment success. Patients increasingly value the ability to maintain independence, preserve meaningful social relationships, and continue participating in activities that contribute to personal well-being.

Evidence from randomized controlled trials has consistently shown that early palliative care integration improves quality-of-life indicators among patients with advanced malignancies [19,20]. These improvements arise from comprehensive approaches that combine symptom management, emotional support, patient education, and individualized care planning. By addressing multiple dimensions of health simultaneously, palliative care contributes to a more holistic patient experience.

The strong representation of quality-of-life outcomes highlights the growing emphasis on patient-centered care within oncology and reflects a broader shift toward evaluating healthcare success through outcomes that matter directly to patients.

Psychological well-being accounted for 18% of reported benefits. Advanced cancer frequently generates significant emotional distress affecting both patients and family members. Anxiety, depression, fear of disease progression, uncertainty regarding treatment outcomes, and concerns about mortality may substantially affect mental health and overall quality of life.

Palliative care teams are uniquely positioned to address these challenges through counseling, psychosocial interventions, family support, and communication strategies designed to reduce emotional burden [10,17]. Several studies included in the review reported improvements in emotional adjustment, reduced depressive symptoms, and enhanced coping mechanisms among patients receiving integrated palliative care services [4,19].

The findings suggest that psychological support should be considered a fundamental component of comprehensive cancer care rather than an optional adjunctive service. Addressing emotional health contributes directly to treatment adherence, patient satisfaction, and overall well-being.

Communication and shared decision-making represented 14% of the observed distribution. Effective communication is increasingly recognized as a critical determinant of high-quality oncology care, particularly in advanced disease settings where treatment decisions are often complex and value-sensitive.

Integrated palliative care promotes structured discussions regarding prognosis, treatment goals, patient preferences, advance care planning, and expectations for future care [17]. These conversations facilitate informed decision-making and ensure that therapeutic interventions remain aligned with individual patient values.

The literature indicates that patients who participate in shared decision-making processes frequently report greater confidence in treatment choices, improved understanding of their disease, and higher levels of trust in healthcare providers [10]. Consequently, communication serves as a key mechanism through which palliative care enhances patient-centered outcomes.

Satisfaction with care accounted for 11% of reported benefits. Patient satisfaction reflects the overall perception of healthcare quality and encompasses multiple dimensions, including communication effectiveness, symptom management, accessibility of services, emotional support, and coordination of care.

Studies evaluating integrated oncology-palliative care models consistently report higher satisfaction levels among patients and caregivers compared with conventional care approaches [8,20]. These improvements are often attributed to enhanced continuity of care, multidisciplinary collaboration, and increased responsiveness to patient needs.

Higher satisfaction may also contribute indirectly to improved healthcare outcomes by strengthening therapeutic relationships and encouraging active patient participation in care planning.

The final category, **reduction in healthcare utilization burden (8%)**, represented the smallest proportion of observed benefits but remains clinically and economically important. Evidence suggests that integrated palliative care may

reduce unnecessary hospitalizations, emergency department visits, intensive care admissions, and other high-intensity interventions near the end of life [8,17].

By proactively managing symptoms and facilitating advance care planning, palliative care helps prevent avoidable healthcare crises while promoting more appropriate utilization of medical resources. These effects may improve healthcare efficiency and reduce costs without compromising quality of care.

An important observation emerging from Figure 4 is the multidimensional nature of palliative care benefits. Rather than producing improvements in a single clinical domain, integrated palliative care positively influences physical, emotional, social, communicative, and healthcare-system outcomes simultaneously. This broad impact distinguishes palliative care from many disease-specific interventions and reinforces its value within comprehensive oncology programs [10,17].

Another notable finding is the close relationship between symptom control and quality of life. The literature consistently demonstrates that effective symptom management serves as a major determinant of overall well-being in patients with advanced cancer. Improvements in pain control, fatigue reduction, and management of treatment-related adverse effects frequently translate into greater independence, improved mood, and enhanced daily functioning [3,19].

Across the Americas, increasing efforts have been directed toward expanding access to palliative care services. Mexico has developed integrated oncology-palliative care programs within specialized cancer centers, providing important examples of multidisciplinary care implementation [2]. Colombia has strengthened palliative care training and service availability through healthcare policy initiatives and professional development programs [16]. Ecuador has also expanded supportive oncology services, although access disparities continue to exist between different healthcare settings.

Despite these advances, significant challenges remain regarding workforce availability, training capacity, public awareness, and equitable access to specialized palliative care services throughout the region. Addressing these barriers will be essential for ensuring that the benefits observed in the literature can be translated into routine clinical practice across diverse healthcare environments [16].

Figure 5.
Integrated model of precision medicine, radiology, and palliative care.

Integrated Care Component	Relative Contribution to Comprehensive Oncology Care (%)
Precision Diagnostics (Genomics, Biomarkers, Liquid Biopsy)	24
Personalized Therapeutics (Targeted Therapy and Immunotherapy)	22
Advanced Radiological Assessment (Radiomics and Imaging Biomarkers)	19
Symptom Management and Supportive Care	15
Psychosocial and Emotional Support	10
Shared Decision-Making and Care Planning	10

Figure 5 presents the integrated model derived from the synthesis of evidence regarding contemporary management of advanced cancer throughout the Americas. The model illustrates how precision diagnostics, personalized therapeutics, advanced radiological assessment, supportive care interventions, psychosocial support, and shared

decision-making function collectively within a multidisciplinary framework. Rather than operating independently, these components interact continuously to support patient-centered oncology care and optimize both clinical outcomes and quality of life [10,13,15,17].

The largest contribution within the model corresponded to **precision diagnostics (24%)**, emphasizing the fundamental role of molecular characterization in modern oncology. Advances in genomic sequencing, biomarker identification, molecular pathology, and liquid biopsy technologies have transformed the diagnostic process by enabling clinicians to identify actionable genetic alterations and biological pathways associated with tumor development and progression [13].

The evidence reviewed demonstrated that precision diagnostics constitute the foundation upon which personalized treatment strategies are developed. Comprehensive molecular profiling allows healthcare professionals to move beyond conventional histopathological classifications and adopt therapeutic approaches tailored to the unique biological characteristics of individual tumors. This capability is particularly relevant in advanced cancer, where tumor heterogeneity frequently influences treatment response and long-term outcomes [14,15].

The findings indicate that precision diagnostics increasingly serve as the entry point for individualized cancer care, influencing virtually every subsequent stage of clinical management.

Personalized therapeutics represented 22% of the integrated model, making it the second most prominent component. This category encompasses targeted therapies, immunotherapies, biomarker-driven treatments, and individualized therapeutic algorithms developed according to molecular and clinical findings.

The emergence of targeted agents and immune checkpoint inhibitors has significantly altered treatment paradigms across multiple malignancies. Personalized therapeutic strategies allow clinicians to select treatments more likely to produce meaningful clinical responses while minimizing exposure to ineffective interventions and unnecessary toxicity [15]. The literature consistently reports improved treatment precision and more efficient allocation of healthcare resources when molecular information is incorporated into therapeutic planning.

The close proportional relationship between precision diagnostics and personalized therapeutics observed in Figure 5 highlights the interdependence of these components. Effective personalized treatment requires accurate biological characterization, while molecular diagnostics derive clinical value through their ability to guide therapeutic decisions.

Advanced radiological assessment accounted for 19% of the model, reflecting the expanding role of imaging technologies within precision oncology. Modern radiology contributes substantially to diagnosis, staging, treatment planning, response assessment, prognostic evaluation, and surveillance [7].

Radiomics, quantitative imaging analysis, and artificial intelligence-assisted interpretation have introduced new opportunities for extracting clinically meaningful information from imaging studies. These innovations provide noninvasive insights into tumor biology and complement molecular diagnostics by offering additional perspectives regarding disease behavior and therapeutic responsiveness [11].

The integration of imaging biomarkers with genomic and clinical information represents one of the most promising developments identified in the literature. Such multidisciplinary approaches facilitate more accurate patient stratification and support increasingly sophisticated precision medicine strategies [7,11].

Together, precision diagnostics, personalized therapeutics, and advanced radiological assessment comprise 65% of the overall model, illustrating the central importance of technological innovation within modern oncology practice.

However, the results also demonstrate that technological advances alone are insufficient to address the full spectrum of patient needs associated with advanced cancer.

Symptom management and supportive care represented 15% of the integrated model. This finding reflects the recognition that effective cancer treatment extends beyond disease control and must also address the physical burden imposed by both malignancy and therapy. Pain, fatigue, dyspnea, gastrointestinal symptoms, sleep disturbances, and treatment-related adverse effects remain major determinants of patient well-being and functional status [17,19].

The literature consistently demonstrates that supportive care interventions improve symptom control, facilitate treatment adherence, and contribute to enhanced quality of life. Importantly, symptom management often influences the feasibility of continuing disease-directed therapies, thereby indirectly affecting clinical outcomes [10].

The substantial contribution of supportive care within the model reinforces the concept that quality cancer care requires simultaneous attention to therapeutic efficacy and patient comfort.

Psychosocial and emotional support accounted for 10% of the model. Although smaller in proportion than technological components, its importance remains considerable. Advanced cancer frequently affects emotional well-being, family relationships, social functioning, financial stability, and psychological resilience.

Evidence indicates that interventions addressing anxiety, depression, uncertainty, existential distress, and caregiver burden contribute significantly to overall quality of life [4,17]. Psychologists, social workers, palliative care specialists, spiritual care providers, and multidisciplinary teams play critical roles in supporting patients and families throughout the disease trajectory.

The findings suggest that psychosocial support should be viewed as an integral component of oncology care rather than a secondary service provided only in specific circumstances.

The final component, **shared decision-making and care planning (10%)**, reflects the growing emphasis on patient autonomy and patient-centered healthcare delivery. Advances in precision medicine have expanded therapeutic options, but they have also increased the complexity of clinical decisions faced by patients and healthcare professionals.

Shared decision-making facilitates meaningful discussions regarding treatment goals, expected outcomes, potential toxicities, quality-of-life considerations, and personal values [10,17]. Such conversations ensure that clinical recommendations align with individual patient preferences and support informed participation in care planning.

The literature consistently identifies effective communication as a major determinant of patient satisfaction, treatment adherence, and trust in healthcare providers. Consequently, decision-making processes represent a critical bridge connecting technological innovation with individualized patient care.

A particularly important observation emerging from Figure 5 is the balance between scientific innovation and human-centered care. While precision diagnostics, personalized therapeutics, and advanced imaging collectively account for nearly two-thirds of the integrated model, supportive care, psychosocial interventions, and communication-related components represent the remaining third. This distribution highlights the contemporary understanding that optimal oncology outcomes depend upon both technological excellence and compassionate multidisciplinary care [10,17].

Another notable finding is the strong interconnectivity among all six components. Molecular diagnostics influence therapeutic decisions; radiological assessment guides monitoring and prognostication; symptom management affects treatment tolerance; psychosocial support improves patient resilience; and shared decision-making ensures alignment between medical recommendations and personal goals. The effectiveness of the overall system therefore depends on coordination among all participating disciplines.

Regional evidence from Mexico, Colombia, and Ecuador further supports this integrated perspective. Although availability of advanced molecular technologies varies among healthcare systems, successful oncology programs increasingly emphasize multidisciplinary collaboration, supportive care integration, and patient-centered approaches alongside technological innovation [2,5,16]. These experiences suggest that sustainable improvements in cancer outcomes require simultaneous investment in infrastructure, workforce development, supportive services, and equitable access to care.

DISCUSSION

The findings of this review highlight a profound transformation in the management of advanced cancer throughout the Americas, characterized by the convergence of precision medicine, advanced radiological technologies, and comprehensive palliative care. The evidence analyzed suggests that contemporary oncology is progressively moving away from traditional disease-centered models toward integrated, patient-centered approaches that combine technological innovation with holistic supportive care. This evolution reflects broader changes in healthcare systems, scientific research, and clinical practice aimed at improving both survival outcomes and quality of life among individuals living with advanced malignancies.

One of the most important observations emerging from the results is the dominant role of precision medicine within modern oncology care. The increasing availability of molecular diagnostics, genomic profiling, biomarker-guided treatment selection, and targeted therapies has fundamentally altered therapeutic decision-making processes. Previous studies have demonstrated that molecular characterization enables clinicians to identify biologically relevant alterations and match patients with therapies that are more likely to provide clinical benefit [13,15]. The findings of the present review support this perspective by showing that precision diagnostics and personalized therapeutics represent the largest components of the contemporary cancer care model.

These observations are consistent with the work of Mateo et al. [15], who emphasized the importance of structured frameworks for interpreting genomic information and translating molecular findings into clinical practice. Similarly, the MOSCATO trial demonstrated that comprehensive molecular profiling can identify actionable targets in a substantial proportion of patients with advanced cancers, thereby supporting individualized treatment strategies [14]. The current review extends these observations by highlighting how precision medicine increasingly influences multiple stages of care, including diagnosis, prognosis, treatment monitoring, and long-term management.

However, the findings also suggest that the benefits of precision medicine are not distributed equally throughout the Americas. Significant regional disparities were observed in the availability of molecular diagnostics, access to targeted therapies, immunotherapy utilization, and participation in clinical research. North America demonstrated the highest implementation levels across all evaluated indicators, whereas Central America and the Caribbean exhibited more limited access to advanced oncological technologies. South America occupied an intermediate position, reflecting substantial progress but persistent variability among countries and healthcare systems.

These disparities have important implications for healthcare equity. Although scientific innovation continues to accelerate, unequal access to molecular technologies may widen existing differences in cancer outcomes between regions and populations. Similar concerns have been reported in studies examining precision oncology implementation in Latin America, where financial limitations, infrastructure constraints, and shortages of specialized personnel continue to influence healthcare delivery [5]. Consequently, the findings support ongoing efforts aimed at expanding access to genomic medicine and reducing barriers that prevent equitable implementation of personalized oncology services.

The results also emphasize the increasingly important role of advanced radiology in modern cancer management. Imaging technologies were found to contribute substantially across the entire continuum of care, from initial diagnosis and staging to treatment planning, response assessment, prognostic evaluation, and surveillance. These findings reinforce the concept that radiology has evolved beyond a purely diagnostic discipline and now functions as an essential component of precision oncology [7].

Particularly noteworthy is the growing influence of radiomics and artificial intelligence within oncological imaging. Quantitative image analysis provides opportunities to extract biologically relevant information that may not be apparent through conventional visual interpretation. Previous investigations have suggested that radiomic signatures may correlate with molecular characteristics, treatment response, and survival outcomes [11]. The findings of the present review support the potential value of integrating imaging biomarkers with genomic and clinical data to enhance patient stratification and optimize individualized treatment planning.

The convergence of radiology and molecular oncology represents one of the most promising developments identified in this review. Historically, imaging and genomics evolved as relatively independent fields. Contemporary evidence increasingly demonstrates that combining these sources of information can provide a more comprehensive understanding of tumor biology and disease behavior [7,11]. Such integration may facilitate the development of highly personalized treatment strategies capable of addressing the considerable heterogeneity observed among patients with advanced cancer.

Equally important are the findings related to integrated palliative care. The results consistently demonstrated that early palliative care contributes to improvements in symptom control, quality of life, psychological well-being, communication, patient satisfaction, and healthcare utilization. These observations align closely with landmark studies conducted by Temel et al. [19] and Zimmermann et al. [20], both of which reported significant benefits associated with early palliative care integration.

The implications of these findings extend beyond symptom management alone. The evidence suggests that palliative care functions as a critical mechanism for aligning therapeutic interventions with patient goals and preferences. By facilitating communication, supporting shared decision-making, and addressing psychosocial concerns, palliative care contributes to a more individualized and human-centered model of oncology practice [10,17]. This perspective challenges historical misconceptions that palliative care should be reserved exclusively for end-of-life situations.

The review further highlights the importance of multidisciplinary collaboration. Advanced cancer care increasingly requires coordinated participation from oncologists, radiologists, molecular pathologists, genetic counselors, palliative care specialists, nurses, psychologists, rehabilitation professionals, and healthcare administrators. The findings indicate that multidisciplinary care models improve coordination, enhance decision-making processes, and support comprehensive management of complex patient needs.

The significance of multidisciplinary care becomes particularly evident when considering the complexity of contemporary treatment decisions. Precision medicine frequently generates large volumes of molecular information that require expert interpretation. Advanced imaging technologies produce increasingly sophisticated diagnostic data, while palliative care considerations introduce additional dimensions related to quality of life, symptom burden, and patient preferences. Effective integration of these diverse factors depends upon collaboration among multiple healthcare disciplines.

A particularly relevant discussion point concerns the relationship between technological innovation and patient-centered care. The results demonstrate that although precision diagnostics, advanced imaging, and personalized therapeutics constitute major components of modern oncology, supportive care, psychosocial interventions, and communication remain essential determinants of overall outcomes. This balance suggests that technological progress alone is insufficient to achieve optimal cancer care.

The evidence reviewed indicates that successful oncology programs combine scientific innovation with compassionate, individualized care. Such integration ensures that treatment decisions are informed not only by biological characteristics but also by patient values, goals, functional status, and quality-of-life considerations. Consequently, the future of oncology may depend less on choosing between technological advancement and supportive care and more on effectively integrating both approaches within comprehensive care models.

The experiences reported from Mexico, Colombia, and Ecuador provide valuable insights regarding implementation within middle-income healthcare systems. Mexico has demonstrated notable progress in integrating oncology and palliative care services within specialized cancer centers, while Colombia has expanded palliative care initiatives through healthcare policy reforms and professional training programs [2,16]. Ecuador has similarly advanced efforts to strengthen cancer care services and improve access to evidence-based interventions. These examples illustrate that meaningful progress is achievable despite resource limitations, particularly when supported by multidisciplinary collaboration and strategic investment in healthcare infrastructure.

Nevertheless, several challenges remain. Persistent disparities in access to molecular diagnostics, advanced imaging technologies, specialized oncology services, and palliative care continue to affect patient outcomes throughout the region. Workforce shortages, financial constraints, limited research infrastructure, and geographic barriers represent ongoing obstacles to implementation. Addressing these challenges will require coordinated efforts involving healthcare institutions, policymakers, academic organizations, and international partners.

The findings of this review also have implications for future research. Continued investigation is needed to evaluate the long-term effectiveness of integrated care models, identify strategies for improving healthcare equity, and assess emerging technologies such as artificial intelligence-driven diagnostics, liquid biopsy applications, and advanced radiomic analyses. Further research involving Latin American populations is particularly important because much of the existing evidence originates from high-income countries with different healthcare structures and resource availability.

Several limitations should be considered when interpreting these findings. As a narrative review, the study synthesizes evidence derived from multiple study designs and healthcare contexts. Variability in methodologies, patient populations, and outcome measures may influence comparisons among studies. Additionally, rapid advances in oncology technologies mean that new evidence continues to emerge, potentially altering future interpretations of current findings.

Despite these limitations, the review provides a comprehensive overview of the evolving relationship among precision medicine, advanced radiology, and palliative care in advanced cancer management. The evidence consistently supports the concept that optimal oncology outcomes are achieved through integrated approaches that combine technological innovation with comprehensive supportive care.

In summary, the discussion highlights that the future of advanced cancer care in the Americas will likely depend upon the successful integration of molecular diagnostics, personalized therapeutics, advanced imaging technologies, multidisciplinary collaboration, and patient-centered supportive care. Precision medicine offers unprecedented opportunities to individualize treatment, while palliative care ensures that therapeutic decisions remain aligned with patient goals and quality-of-life priorities. Together, these approaches form the foundation of a modern oncology paradigm capable of addressing the biological complexity of cancer while preserving the human dimensions of care [10,13,15,17].

CONCLUSION

The present review demonstrates that the integration of precision medicine, advanced radiological technologies, and comprehensive palliative care represents one of the most significant developments in contemporary oncology. The evidence analyzed throughout this study indicates that advanced cancer management is increasingly characterized by multidisciplinary, patient-centered approaches that combine scientific innovation with holistic supportive care. This transformation reflects a growing recognition that optimal oncological outcomes depend not only on disease control but also on quality of life, symptom management, psychosocial well-being, and alignment of treatment strategies with individual patient goals.

The findings confirm that precision medicine has become a cornerstone of modern cancer care. Advances in molecular diagnostics, genomic profiling, biomarker identification, liquid biopsy technologies, targeted therapies, and immunotherapy have substantially improved the ability to personalize treatment according to the biological characteristics of individual tumors. These innovations contribute to more accurate therapeutic selection, improved treatment efficiency, and reduced exposure to ineffective interventions. Consequently, precision oncology has expanded beyond a technological innovation and now serves as a fundamental framework for individualized clinical decision-making.

Similarly, advanced radiology has evolved into an indispensable component of the precision oncology paradigm. Modern imaging technologies, radiomics, quantitative imaging biomarkers, and artificial intelligence-assisted analyses contribute throughout the entire cancer care continuum, including diagnosis, staging, treatment planning, response evaluation, prognostic assessment, and surveillance. The growing integration of radiological and molecular information provides a more comprehensive understanding of tumor behavior and supports increasingly sophisticated approaches to personalized treatment planning.

The review also demonstrates that comprehensive palliative care plays a critical role in improving outcomes among patients with advanced cancer. Evidence consistently indicates that early integration of palliative care contributes to better symptom control, enhanced quality of life, improved psychological well-being, more effective communication, greater patient satisfaction, and more appropriate utilization of healthcare resources. These findings reinforce the concept that palliative care should be incorporated as a routine component of oncology services rather than being reserved exclusively for end-of-life care.

An important conclusion emerging from the analysis is that technological innovation alone is insufficient to address the multidimensional challenges associated with advanced cancer. Although molecular diagnostics, targeted therapies, immunotherapy, and advanced imaging technologies have expanded therapeutic possibilities, their benefits are maximized when combined with supportive care interventions that address physical, emotional, social, and existential needs. The most effective models of care identified in the literature were those that successfully integrated precision medicine with comprehensive patient-centered support.

The study further highlights the essential role of multidisciplinary collaboration. Oncologists, radiologists, pathologists, molecular biologists, genetic counselors, palliative care specialists, nurses, psychologists, rehabilitation professionals, and healthcare administrators all contribute unique expertise that supports comprehensive cancer management. Effective coordination among these disciplines facilitates informed decision-making, improves continuity of care, and enhances the overall patient experience.

From a regional perspective, the review reveals substantial progress in the implementation of precision oncology and integrated palliative care throughout the Americas. However, important disparities remain regarding access to molecular diagnostics, advanced imaging technologies, innovative therapeutics, clinical trials, and specialized supportive care services. North America generally demonstrates greater availability of these resources, whereas several countries in Latin America and the Caribbean continue to face infrastructural, financial, and workforce-related challenges. Nevertheless, experiences from Mexico, Colombia, and Ecuador illustrate meaningful advances and demonstrate the feasibility of implementing integrated oncology models within diverse healthcare environments.

The findings underscore the importance of continuing efforts aimed at reducing inequities in cancer care. Expanding access to precision medicine, strengthening radiological infrastructure, increasing availability of palliative care services, promoting professional training, and fostering international collaboration will be essential for ensuring that advances in oncology benefit patients across all regions of the continent. Policymakers, healthcare institutions, academic organizations, and professional societies must work collaboratively to develop sustainable strategies that improve accessibility while maintaining high standards of care.

The review also identifies several opportunities for future development. Emerging technologies such as artificial intelligence, advanced radiomics, liquid biopsy platforms, machine learning applications, and integrated digital health systems are likely to further transform cancer care during the coming years. Continued research is needed to evaluate their effectiveness, cost-efficiency, and applicability within diverse healthcare settings. Additionally, greater inclusion of Latin American populations in oncology research may help generate evidence that is more representative of regional realities and healthcare needs.

In conclusion, the future of advanced cancer care in the Americas lies in the successful integration of precision diagnostics, personalized therapeutics, advanced radiological assessment, multidisciplinary collaboration, and comprehensive palliative care. Together, these elements create a modern oncology model that addresses both the biological complexity of cancer and the multidimensional needs of patients. By combining technological innovation with compassionate, patient-centered care, healthcare systems can achieve meaningful improvements in survival, quality of life, treatment experiences, and overall health outcomes among individuals living with advanced malignancies. The evidence reviewed strongly supports the continued development and expansion of integrated oncology frameworks as a pathway toward more effective, equitable, and humanized cancer care throughout the continent.

REFERENCES

- [1] S. R. Alcorn et al., "External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline," *Practical Radiation Oncology*, vol. 14, no. 5, pp. 345–358, 2024.
- [2] S. R. Allende-Pérez et al., "Integrated Oncology and Palliative Care: Five Years Experience at the National Cancer Institute of Mexico," *Salud Pública de México*, vol. 58, no. 2, pp. 317–324, 2016.
- [3] M. Bakitas et al., "Effects of a Palliative Care Intervention on Clinical Outcomes in Patients with Advanced Cancer," *JAMA*, vol. 302, no. 7, pp. 741–749, 2009.
- [4] M. A. Bakitas et al., "Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial," *Journal of Clinical Oncology*, vol. 33, no. 13, pp. 1438–1445, 2015.
- [5] A. Calderón-Aparicio et al., "Precision Oncology in Latin America: Current Situation, Challenges and Perspectives," *ecancermedicalscience*, vol. 13, p. 993, 2019.
- [6] Y. Chávarri-Guerra et al., "Providing Supportive and Palliative Care Using Telemedicine for Patients with Advanced Cancer During the COVID-19 Pandemic in Mexico," *The Oncologist*, vol. 26, no. 3, pp. e512–e515, 2021.
- [7] I. Dregely et al., "Imaging Biomarkers in Oncology: Basics and Application to MRI," *Journal of Magnetic Resonance Imaging*, vol. 48, no. 1, pp. 13–26, 2018.
- [8] J. J. Fulton et al., "Integrated Outpatient Palliative Care for Patients with Advanced Cancer: A Systematic Review and Meta-Analysis," *Palliative Medicine*, vol. 33, no. 2, pp. 123–134, 2019.

- [9] M. W. Haun et al., "Early Palliative Care for Adults with Advanced Cancer," *Cochrane Database of Systematic Reviews*, no. 6, Art. no. CD011129, 2017.
- [10] D. Hui and E. Bruera, "Integrating Palliative Care into the Trajectory of Cancer Care," *Nature Reviews Clinical Oncology*, vol. 13, no. 3, pp. 159–171, 2016.
- [11] A. K. Jha et al., "Emerging Role of Quantitative Imaging (Radiomics) and Artificial Intelligence in Precision Oncology," *Exploration of Targeted Anti-tumor Therapy*, vol. 4, no. 4, pp. 569–582, 2023.
- [12] A. Lara-Solares et al., "Latin-American Guidelines for Cancer Pain Management," *Pain Management*, vol. 7, no. 4, pp. 287–298, 2017.
- [13] E. R. Malone, O. S. Oliva, P. J. Sabatini, J. B. Stockley, and M. Siu, "Molecular Profiling for Precision Cancer Therapies," *Genome Medicine*, vol. 12, no. 8, pp. 1–19, 2020.
- [14] C. Massard et al., "High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial," *Cancer Discovery*, vol. 7, no. 6, pp. 586–595, 2017.
- [15] J. Mateo et al., "A Framework to Rank Genomic Alterations as Targets for Cancer Precision Medicine: The ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)," *Annals of Oncology*, vol. 29, no. 9, pp. 1895–1902, 2018.
- [16] J. Reid et al., "Palliative Care and Oncology in Colombia: The Potential of Integrated Care Delivery," *Current Oncology*, vol. 28, no. 4, pp. 2441–2452, 2021.
- [17] J. J. Sanders et al., "Palliative Care for Patients with Cancer: ASCO Guideline Update," *Journal of Clinical Oncology*, vol. 42, no. 19, pp. 2336–2357, 2024.
- [18] L. Seymour et al., "iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics," *The Lancet Oncology*, vol. 18, no. 3, pp. e143–e152, 2017.
- [19] J. S. Temel et al., "Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer," *The New England Journal of Medicine*, vol. 363, no. 8, pp. 733–742, 2010.
- [20] C. Zimmermann et al., "Early Palliative Care for Patients with Advanced Cancer: A Cluster-Randomised Controlled Trial," *The Lancet*, vol. 383, no. 9930, pp. 1721–1730, 2014.